Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

The president of AstraZeneca’s China division has been placed under investigation by local police, as Beijing advances an anti-corruption crackdown in the healthcare sector ...

AstraZeneca suffered a £14bn share price hit on Tuesday after Chinese media reported more details about an investigation into the British drug giant. Shares plunged 8.4pc, the most in four years ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

A fraud investigation linked to AstraZeneca (NASDAQ:AZN) has expanded to several government agencies, implicating dozens of senior executives at the company as of last week, Shanghai-based ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...